Annual report
3079.TEDINET S100TVMM
Period2023-04-01 → 2024-03-31
Filed2024-07-01
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥45.9bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥47.5bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥45.5bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥41.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥44.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥653m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥1.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥663m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.4bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥376m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.4bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥173m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥936m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥863m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥572m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥792m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥22.7bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥23.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥22.2bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥20.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥20.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥13.5bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥14.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥9.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥9.3bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.6bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥7.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.6bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥8.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥7.5bn | at 2024-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥8.6bn | at 2023-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2022-03-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2021-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥5.2bn | at 2020-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥423m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.5bn | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥397m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥477m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥97m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥217m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥362m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥312m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥245m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥235m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥274m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥747m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥16.58 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.21 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.56 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.6 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.56 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥90.04 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.33 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥55.5 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥50 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥880.72 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥894.19 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥828.27 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥767.76 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥735.76 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 40.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 10,780,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,780,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,780,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,780,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 316 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 319 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 328 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 330 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 322 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 17
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥4.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥4.1bn |
| Arrhythmia Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥39.3bn |
| Arrhythmia Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥39.3bn |
| Ischemia Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.5bn |
| Ischemia Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.5bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥41.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥41.8bn |
| Total Of Reportable Segments And Otherssegment total | employees | at 2024-03-31 | 316 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Arrhythmia Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥40.9bn |
| Arrhythmia Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥40.9bn |
| Ischemia Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥3.1bn |
| Ischemia Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥3.1bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥43.9bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥43.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 942
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 147595000 | JPY |
| Research and development expenses sga | Prior1YearDuration_NonConsolidatedMember | 15426000 | JPY |
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 30991000 | JPY |
| Revenues from external customers | Prior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000ArrhythmiaBusinessReportableSegmentMember | 40858153000 | JPY |
| Revenues from external customers | Prior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000IschemiaBusinessReportableSegmentMember | 3059612000 | JPY |
| Revenues from external customers | Prior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember | 43917766000 | JPY |
| Revenues from external customers | Prior1YearDuration_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3565991000 | JPY |
| Revenues from external customers | Prior1YearDuration_NonConsolidatedMember | 47483757000 | JPY |
| Transactions with other segments | Prior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000ArrhythmiaBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000IschemiaBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000ArrhythmiaBusinessReportableSegmentMember | 40858153000 | JPY |
| Net sales | Prior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000IschemiaBusinessReportableSegmentMember | 3059612000 | JPY |
| Net sales | Prior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember | 43917766000 | JPY |
| Net sales | Prior1YearDuration_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3565991000 | JPY |
| Net sales | Prior1YearDuration_NonConsolidatedMember | 47483757000 | JPY |
| Gross profit | Prior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000ArrhythmiaBusinessReportableSegmentMember | 4633179000 | JPY |
| Gross profit | Prior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000IschemiaBusinessReportableSegmentMember | 385570000 | JPY |
| Gross profit | Prior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember | 5018750000 | JPY |
| Gross profit | Prior1YearDuration_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 437313000 | JPY |
| Gross profit | Prior1YearDuration_NonConsolidatedMember | 5456063000 | JPY |
| Revenues from external customers | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000ArrhythmiaBusinessReportableSegmentMember | 39305978000 | JPY |
| Revenues from external customers | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000IschemiaBusinessReportableSegmentMember | 2456059000 | JPY |
| Revenues from external customers | CurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember | 41762037000 | JPY |
| Revenues from external customers | CurrentYearDuration_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4089037000 | JPY |
| Revenues from external customers | CurrentYearDuration_NonConsolidatedMember | 45851074000 | JPY |
| Transactions with other segments | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000ArrhythmiaBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000IschemiaBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_NonConsolidatedMember | － | JPY |
| Net sales | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000ArrhythmiaBusinessReportableSegmentMember | 39305978000 | JPY |
| Net sales | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000IschemiaBusinessReportableSegmentMember | 2456059000 | JPY |
| Net sales | CurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember | 41762037000 | JPY |
| Net sales | CurrentYearDuration_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4089037000 | JPY |
| Net sales | CurrentYearDuration_NonConsolidatedMember | 45851074000 | JPY |
| Gross profit | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000ArrhythmiaBusinessReportableSegmentMember | 3968281000 | JPY |
| Gross profit | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E03005-000IschemiaBusinessReportableSegmentMember | 329349000 | JPY |
| Gross profit | CurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember | 4297630000 | JPY |
| Gross profit | CurrentYearDuration_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 466938000 | JPY |
| Gross profit | CurrentYearDuration_NonConsolidatedMember | 4764568000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-07-01 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第38期(自 2023年４月１日 至 2024年３月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ディーブイエックス株式会社 | |
| Company name in english cover page | FilingDateInstant | DVx Inc. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |